Title :

Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome

Author(s) :

Coly, M. [Auteur]
Adams, D. [Auteur]
Attarian, S. [Auteur]
Bouhour, F. [Auteur]
Camdessanché, J. P. [Auteur]
Carey, G. [Auteur]
Cauquil, C. [Auteur]
Chanson, J. B. [Auteur]
Chrétien, P. [Auteur]
Créange, A. [Auteur]
Delmont, E. [Auteur]
Fargeot, G. [Auteur]
Frachet, S. [Auteur]
Gendre, T. [Auteur]
Kuntzer, T. [Auteur]
Labeyrie, C. [Auteur]
Maisonobe, T. [Auteur]
Michaud, M. [Auteur]
Moulin, M. [Auteur]
Nicolas, G. [Auteur]
Noury, J. B. [Auteur]
Péréon, Y. [Auteur]
Puma, A. [Auteur]
Sole, G. [Auteur]
Taithe, F. [Auteur]
Tard, Celine [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Théaudin, M. [Auteur]
Timsit, S. [Auteur]
Venditti, L. [Auteur]
Echaniz-Laguna, A. [Auteur]

Journal title :

Journal of Neurology

Abbreviated title :

J. Neurol.

Volume number :

271

Pages :

4982–4990

Publication date :

2024-06-08

ISSN :

0340-5354

English keyword(s) :

Anti-GQ1b antibodies
Miller-Fisher syndrome
Bickerstaff's brainstem encephalitis
Guillain-Barre syndrome

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background & purpose In this retrospective study, we aimed at defining the clinical, paraclinical and outcome features of acute neurological syndromes associated with anti-GQ1b antibodies. Results We identified 166 ...
Show more >Background & purpose In this retrospective study, we aimed at defining the clinical, paraclinical and outcome features of acute neurological syndromes associated with anti-GQ1b antibodies. Results We identified 166 patients with neurological symptoms appearing in less than 1 month and anti-GQ1b antibodies in serum between 2012 and 2022. Half were female (51%), mean age was 50 years (4–90), and the most frequent clinical features were areflexia (80% of patients), distal upper and lower limbs sensory symptoms (78%), ophthalmoplegia (68%), sensory ataxia (67%), limb muscle weakness (45%) and bulbar weakness (45%). Fifty-three patients (32%) presented with complete (21%) and incomplete (11%) Miller Fisher syndrome (MFS), thirty-six (22%) with Guillain–Barre syndrome (GBS), one (0.6%) with Bickerstaff encephalitis (BE), and seventy-three (44%) with mixed MFS, GBS & BE clinical features. Nerve conduction studies were normal in 46% of cases, showed demyelination in 28%, and axonal loss in 23%. Anti-GT1a antibodies were found in 56% of cases, increased cerebrospinal fluid protein content in 24%, and Campylobacter jejuni infection in 7%. Most patients (83%) were treated with intravenous immunoglobulins, and neurological recovery was complete in 69% of cases at 1 year follow-up. One patient died, and 15% of patients relapsed. Age > 70 years, initial Intensive Care Unit (ICU) admission, and absent anti-GQ1b IgG antibodies were predictors of incomplete recovery at 12 months. No predictors of relapse were identified. Conclusion This study from Western Europe shows acute anti-GQ1b antibody syndrome presents with a large clinical phenotype, a good outcome in 2/3 of cases, and frequent relapses.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Submission date :

2024-06-09T21:01:24Z
2024-09-05T08:10:49Z